#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-5	Brain	_
1-2	6-15	Circuitry	_
1-3	16-26	Associated	_
1-4	27-31	with	_
1-5	32-35	the	_
1-6	36-47	Development	_
1-7	48-50	of	_
1-8	51-60	Substance	_
1-9	61-64	Use	http://maven.renci.org/NeuroBridge/neurobridge#CurrentUse
1-10	65-67	in	_
1-11	68-75	Bipolar	http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder
1-12	76-84	Disorder	http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder
1-13	85-88	and	_
1-14	89-100	Preliminary	_
1-15	101-109	Evidence	_
1-16	110-113	for	_
1-17	114-120	Sexual	_
1-18	121-131	Dimorphism	_
1-19	132-134	in	_
1-20	135-146	Adolescents	http://maven.renci.org/NeuroBridge/neurobridge#Cholesterol
1-21	147-156	Substance	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-22	157-160	use	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-23	161-170	disorders	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-24	171-172	(	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-25	173-177	SUDs	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-26	178-179	)	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-27	180-183	and	_
1-28	184-188	mood	http://maven.renci.org/NeuroBridge/neurobridge#MoodDisorder
1-29	189-198	disorders	http://maven.renci.org/NeuroBridge/neurobridge#MoodDisorder
1-30	199-202	are	_
1-31	203-209	highly	_
1-32	210-218	comorbid	_
1-33	219-222	and	_
1-34	223-229	confer	_
1-35	230-231	a	_
1-36	232-236	high	_
1-37	237-241	risk	_
1-38	242-245	for	_
1-39	246-253	adverse	_
1-40	254-262	outcomes	_
1-41	263-264	.	_

2-1	265-272	However	_
2-2	273-274	,	_
2-3	275-279	data	_
2-4	280-283	are	_
2-5	284-291	limited	_
2-6	292-294	on	_
2-7	295-298	the	_
2-8	299-317	neurodevelopmental	_
2-9	318-323	basis	_
2-10	324-326	of	_
2-11	327-331	this	_
2-12	332-343	comorbidity	_
2-13	344-345	.	_

3-1	346-355	Substance	_
3-2	356-359	use	_
3-3	360-370	initiation	_
3-4	371-380	typically	_
3-5	381-387	occurs	_
3-6	388-394	during	_
3-7	395-406	adolescence	_
3-8	407-410	and	_
3-9	411-423	sex-specific	_
3-10	424-437	developmental	_
3-11	438-448	mechanisms	_
3-12	449-452	are	_
3-13	453-463	implicated	_
3-14	464-465	.	_

4-1	466-468	In	_
4-2	469-473	this	_
4-3	474-485	preliminary	_
4-4	486-491	study	_
4-5	492-494	we	_
4-6	495-501	review	_
4-7	502-505	the	_
4-8	506-516	literature	_
4-9	517-520	and	_
4-10	521-532	investigate	_
4-11	533-541	regional	_
4-12	542-546	gray	_
4-13	547-553	matter	_
4-14	554-560	volume	_
4-15	561-562	(	_
4-16	563-566	GMV	_
4-17	567-568	)	_
4-18	569-579	associated	_
4-19	580-584	with	_
4-20	585-595	subsequent	_
4-21	596-605	substance	_
4-22	606-609	use	_
4-23	610-618	problems	_
4-24	619-621	in	_
4-25	622-633	adolescents	http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder
4-26	634-638	with	http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder
4-27	639-646	bipolar	http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder
4-28	647-655	disorder	http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder
4-29	656-657	(	http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder
4-30	658-660	BD	http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder
4-31	661-662	)	http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder
4-32	663-666	and	_
4-33	667-674	explore	_
4-34	675-680	these	_
4-35	681-693	associations	_
4-36	694-697	for	_
4-37	698-705	females	_
4-38	706-709	and	_
4-39	710-715	males	_
4-40	716-717	.	_

5-1	718-724	Thirty	_
5-2	725-731	DSM-IV	_
5-3	732-741	diagnosed	_
5-4	742-744	BD	http://maven.renci.org/NeuroBridge/neurobridge#Cholesterol
5-5	745-756	adolescents	http://maven.renci.org/NeuroBridge/neurobridge#Cholesterol
5-6	757-761	with	_
5-7	762-769	minimal	_
5-8	770-787	alcohol/substance	_
5-9	788-796	exposure	_
5-10	797-806	completed	_
5-11	807-815	baseline	_
5-12	816-826	structural	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument
5-13	827-835	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument
5-14	836-845	resonance	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument
5-15	846-853	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument
5-16	854-859	scans	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument
5-17	860-861	.	_

6-1	862-864	At	_
6-2	865-874	follow-up	_
6-3	875-876	(	_
6-4	877-879	on	_
6-5	880-887	average	_
6-6	888-889	6	_
6-7	890-895	years	_
6-8	896-909	post-baseline	_
6-9	910-911	)	_
6-10	912-913	,	_
6-11	914-922	subjects	_
6-12	923-927	were	_
6-13	928-940	administered	_
6-14	941-944	the	_
6-15	945-951	CRAFFT	_
6-16	952-961	interview	_
6-17	962-965	and	_
6-18	966-977	categorized	_
6-19	978-982	into	_
6-20	983-988	those	_
6-21	989-996	scoring	_
6-22	997-999	at	_
6-23	1000-1004	high	_
6-24	1005-1006	(	_
6-25	1007-1008	>	_
6-26	1009-1010	2	_
6-27	1011-1012	:	_
6-28	1013-1023	CRAFFTHIGH	_
6-29	1024-1025	)	_
6-30	1026-1032	versus	_
6-31	1033-1036	low	_
6-32	1037-1038	(	_
6-33	1039-1040	<	_
6-34	1041-1042	2	_
6-35	1043-1044	:	_
6-36	1045-1054	CRAFFTLOW	_
6-37	1055-1056	)	_
6-38	1057-1061	risk	_
6-39	1062-1065	for	_
6-40	1066-1083	alcohol/substance	_
6-41	1084-1092	problems	_
6-42	1093-1094	.	_

7-1	1095-1100	Lower	_
7-2	1101-1104	GMV	_
7-3	1105-1107	in	_
7-4	1108-1118	prefrontal	_
7-5	1119-1120	,	_
7-6	1121-1128	insular	_
7-7	1129-1130	,	_
7-8	1131-1134	and	_
7-9	1135-1147	temporopolar	_
7-10	1148-1156	cortices	_
7-11	1157-1161	were	_
7-12	1162-1170	observed	_
7-13	1171-1173	at	_
7-14	1174-1182	baseline	_
7-15	1183-1188	among	_
7-16	1189-1200	adolescents	_
7-17	1201-1205	with	_
7-18	1206-1208	BD	_
7-19	1209-1218	reporting	_
7-20	1219-1229	subsequent	_
7-21	1230-1237	alcohol	_
7-22	1238-1241	and	_
7-23	1242-1250	cannabis	_
7-24	1251-1254	use	_
7-25	1255-1263	compared	_
7-26	1264-1266	to	_
7-27	1267-1278	adolescents	_
7-28	1279-1283	with	_
7-29	1284-1286	BD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
7-30	1287-1290	who	_
7-31	1291-1294	did	_
7-32	1295-1298	not	_
7-33	1299-1300	(	_
7-34	1301-1302	p	_
7-35	1303-1304	<	_
7-36	1305-1310	0.005	_
7-37	1311-1312	,	_
7-38	1313-1321	clusters	_
7-39	1322-1323	>	_
7-40	1324-1326	20	_
7-41	1327-1333	voxels	_
7-42	1334-1335	)	_
7-43	1336-1337	.	_

8-1	1338-1343	Lower	_
8-2	1344-1356	dorsolateral	_
8-3	1357-1367	prefrontal	_
8-4	1368-1371	GMV	_
8-5	1372-1375	was	_
8-6	1376-1386	associated	_
8-7	1387-1391	with	_
8-8	1392-1398	future	_
8-9	1399-1408	substance	_
8-10	1409-1412	use	_
8-11	1413-1415	in	_
8-12	1416-1420	both	_
8-13	1421-1428	females	_
8-14	1429-1432	and	_
8-15	1433-1438	males	_
8-16	1439-1440	.	_

9-1	1441-1443	In	_
9-2	1444-1451	females	_
9-3	1452-1453	,	_
9-4	1454-1459	lower	_
9-5	1460-1473	orbitofrontal	_
9-6	1474-1477	and	_
9-7	1478-1484	insula	_
9-8	1485-1488	GMV	_
9-9	1489-1492	was	_
9-10	1493-1503	associated	_
9-11	1504-1508	with	_
9-12	1509-1515	future	_
9-13	1516-1525	substance	_
9-14	1526-1529	use	_
9-15	1530-1531	;	_
9-16	1532-1537	while	_
9-17	1538-1540	in	_
9-18	1541-1546	males	_
9-19	1547-1548	,	_
9-20	1549-1554	lower	_
9-21	1555-1562	rostral	_
9-22	1563-1573	prefrontal	_
9-23	1574-1577	GMV	_
9-24	1578-1581	was	_
9-25	1582-1592	associated	_
9-26	1593-1597	with	_
9-27	1598-1604	future	_
9-28	1605-1608	use	_
9-29	1609-1610	.	_

10-1	1611-1616	Lower	_
10-2	1617-1630	orbitofrontal	_
10-3	1631-1632	,	_
10-4	1633-1640	insular	_
10-5	1641-1644	and	_
10-6	1645-1657	temporopolar	_
10-7	1658-1661	GMV	_
10-8	1662-1665	was	_
10-9	1666-1674	observed	_
10-10	1675-1677	in	_
10-11	1678-1683	those	_
10-12	1684-1687	who	_
10-13	1688-1700	transitioned	_
10-14	1701-1703	to	_
10-15	1704-1711	smoking	_
10-16	1712-1719	tobacco	_
10-17	1720-1721	.	_

11-1	1722-1730	Findings	_
11-2	1731-1739	indicate	_
11-3	1740-1743	GMV	_
11-4	1744-1755	development	_
11-5	1756-1758	is	_
11-6	1759-1769	associated	_
11-7	1770-1774	with	_
11-8	1775-1779	risk	_
11-9	1780-1783	for	_
11-10	1784-1790	future	_
11-11	1791-1800	substance	_
11-12	1801-1804	use	http://maven.renci.org/NeuroBridge/neurobridge#CurrentUse
11-13	1805-1813	problems	_
11-14	1814-1816	in	_
11-15	1817-1828	adolescents	_
11-16	1829-1833	with	_
11-17	1834-1836	BD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
11-18	1837-1838	,	_
11-19	1839-1843	with	_
11-20	1844-1851	results	_
11-21	1852-1863	implicating	_
11-22	1864-1867	GMV	_
11-23	1868-1879	development	_
11-24	1880-1882	in	_
11-25	1883-1890	regions	_
11-26	1891-1901	subserving	_
11-27	1902-1911	emotional	_
11-28	1912-1922	regulation	_
11-29	1923-1925	in	_
11-30	1926-1933	females	_
11-31	1934-1937	and	_
11-32	1938-1945	regions	_
11-33	1946-1956	subserving	_
11-34	1957-1966	executive	_
11-35	1967-1976	processes	_
11-36	1977-1980	and	_
11-37	1981-1990	attention	_
11-38	1991-1993	in	_
11-39	1994-1999	males	_
11-40	2000-2001	.	_

12-1	2002-2011	Graphical	_
12-2	2012-2020	abstract	_
12-3	2021-2025	This	_
12-4	2026-2031	study	_
12-5	2032-2044	demonstrates	_
12-6	2045-2053	regional	_
12-7	2054-2058	gray	_
12-8	2059-2065	matter	_
12-9	2066-2072	volume	_
12-10	2073-2082	decreases	_
12-11	2083-2087	that	_
12-12	2088-2091	may	_
12-13	2092-2103	distinguish	_
12-14	2104-2115	adolescents	_
12-15	2116-2120	with	_
12-16	2121-2128	Bipolar	_
12-17	2129-2137	Disorder	http://maven.renci.org/NeuroBridge/neurobridge#MovementDisorder
12-18	2138-2141	and	_
12-19	2142-2150	elevated	_
12-20	2151-2155	risk	_
12-21	2156-2159	for	_
12-22	2160-2166	future	_
12-23	2167-2176	substance	_
12-24	2177-2180	use	_
12-25	2181-2189	problems	_
12-26	2190-2191	.	_

13-1	2192-2203	Preliminary	_
13-2	2204-2212	findings	_
13-3	2213-2220	suggest	_
13-4	2221-2223	in	_
13-5	2224-2231	females	_
13-6	2232-2233	,	_
13-7	2234-2241	regions	_
13-8	2242-2252	associated	_
13-9	2253-2257	with	_
13-10	2258-2271	internalizing	_
13-11	2272-2280	behavior	_
13-12	2281-2284	and	_
13-13	2285-2294	affective	_
13-14	2295-2305	processing	_
13-15	2306-2309	are	_
13-16	2310-2317	related	_
13-17	2318-2320	to	_
13-18	2321-2325	risk	_
13-19	2326-2327	;	_
13-20	2328-2330	in	_
13-21	2331-2336	males	_
13-22	2337-2338	,	_
13-23	2339-2346	regions	_
13-24	2347-2357	associated	_
13-25	2358-2362	with	_
13-26	2363-2372	attention	_
13-27	2373-2376	and	_
13-28	2377-2382	other	_
13-29	2383-2392	executive	_
13-30	2393-2402	processes	_
13-31	2403-2404	.	_

14-1	2405-2414	MATERIALS	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
14-2	2415-2418	AND	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
14-3	2419-2426	METHODS	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
14-4	2427-2439	Participants	_
14-5	2440-2448	Subjects	_
14-6	2449-2452	who	_
14-7	2453-2457	were	_
14-8	2458-2466	assessed	_
14-9	2467-2470	and	_
14-10	2471-2478	scanned	_
14-11	2479-2481	in	_
14-12	2482-2483	a	_
14-13	2484-2499	cross-sectional	_
14-14	2500-2505	study	_
14-15	2506-2509	and	_
14-16	2510-2519	consented	_
14-17	2520-2522	to	_
14-18	2523-2528	being	_
14-19	2529-2541	re-contacted	_
14-20	2542-2546	were	_
14-21	2547-2559	re-contacted	_
14-22	2560-2563	and	_
14-23	2564-2573	recruited	_
14-24	2574-2576	if	_
14-25	2577-2581	they	_
14-26	2582-2585	met	_
14-27	2586-2595	inclusion	_
14-28	2596-2599	and	_
14-29	2600-2603	did	_
14-30	2604-2607	not	_
14-31	2608-2612	meet	_
14-32	2613-2622	exclusion	_
14-33	2623-2631	criteria	_
14-34	2632-2633	.	_

15-1	2634-2646	Participants	_
15-2	2647-2655	included	_
15-3	2656-2658	30	_
15-4	2659-2676	adolescents/young	http://maven.renci.org/NeuroBridge/neurobridge#YoungManiaRatingScale
15-5	2677-2683	adults	http://maven.renci.org/NeuroBridge/neurobridge#YoungManiaRatingScale
15-6	2684-2693	diagnosed	http://maven.renci.org/NeuroBridge/neurobridge#YoungManiaRatingScale
15-7	2694-2698	with	http://maven.renci.org/NeuroBridge/neurobridge#YoungManiaRatingScale
15-8	2699-2701	BD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
15-9	2702-2703	[	_
15-10	2704-2708	mean	_
15-11	2709-2712	age	_
15-12	2713-2715	at	_
15-13	2716-2724	baseline	_
15-14	2725-2726	+	_
15-15	2727-2735	standard	_
15-16	2736-2745	deviation	_
15-17	2746-2747	(	_
15-18	2748-2750	SD	_
15-19	2751-2752	)	_
15-20	2753-2754	=	_
15-21	2755-2759	16+2	_
15-22	2760-2765	years	_
15-23	2766-2767	;	_
15-24	2768-2770	29	_
15-25	2771-2772	(	_
15-26	2773-2775	97	_
15-27	2776-2777	%	_
15-28	2778-2779	)	_
15-29	2780-2783	BDI	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
15-30	2784-2785	,	_
15-31	2786-2787	1	_
15-32	2788-2789	(	_
15-33	2790-2791	3	_
15-34	2792-2793	%	_
15-35	2794-2795	)	_
15-36	2796-2800	BDII	_
15-37	2801-2802	;	_
15-38	2803-2805	50	_
15-39	2806-2807	%	_
15-40	2808-2814	female	_
15-41	2815-2816	;	_
15-42	2817-2821	mean	_
15-43	2822-2825	age	_
15-44	2826-2828	at	_
15-45	2829-2839	follow-up=	_
15-46	2840-2844	22+3	_
15-47	2845-2850	years	_
15-48	2851-2852	]	_
15-49	2853-2854	(	_
15-50	2855-2858	see	_
15-51	2859-2864	Table	_
15-52	2865-2866	1	_
15-53	2867-2870	for	_
15-54	2871-2882	participant	_
15-55	2883-2899	characterization	_
15-56	2900-2901	)	_
15-57	2902-2903	.	_

16-1	2904-2907	The	_
16-2	2908-2924	presence/absence	_
16-3	2925-2927	of	_
16-4	2928-2939	psychiatric	_
16-5	2940-2949	diagnoses	_
16-6	2950-2953	and	_
16-7	2954-2958	mood	_
16-8	2959-2964	state	_
16-9	2965-2967	at	_
16-10	2968-2972	time	_
16-11	2973-2975	of	_
16-12	2976-2988	neuroimaging	_
16-13	2989-2993	were	_
16-14	2994-3003	confirmed	_
16-15	3004-3008	with	_
16-16	3009-3012	the	_
16-17	3013-3023	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-18	3024-3032	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-19	3033-3042	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-20	3043-3046	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-21	3047-3053	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-22	3054-3063	Diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-23	3064-3067	for	_
16-24	3068-3080	participants	_
16-25	3081-3084	≥18	_
16-26	3085-3090	years	_
16-27	3091-3094	and	_
16-28	3095-3098	the	_
16-29	3099-3114	Kiddie-Schedule	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale
16-30	3115-3118	for	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale
16-31	3119-3128	Affective	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
16-32	3129-3138	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
16-33	3139-3142	and	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
16-34	3143-3156	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
16-35	3157-3160	for	_
16-36	3161-3173	participants	_
16-37	3174-3175	<	_
16-38	3176-3178	18	_
16-39	3179-3184	years	_
16-40	3185-3186	.	_

17-1	3187-3189	At	_
17-2	3190-3198	baseline	_
17-3	3199-3209	assessment	_
17-4	3210-3211	,	_
17-5	3212-3215	all	_
17-6	3216-3228	participants	_
17-7	3229-3238	completed	_
17-8	3239-3243	sMRI	http://maven.renci.org/NeuroBridge/neurobridge#Thing
17-9	3244-3245	.	_

18-1	3246-3248	At	_
18-2	3249-3258	follow-up	_
18-3	3259-3269	assessment	_
18-4	3270-3271	,	_
18-5	3272-3274	on	_
18-6	3275-3282	average	_
18-7	3283-3286	6+2	_
18-8	3287-3292	years	_
18-9	3293-3298	after	_
18-10	3299-3307	baseline	_
18-11	3308-3318	assessment	_
18-12	3319-3320	,	_
18-13	3321-3329	subjects	_
18-14	3330-3339	completed	_
18-15	3340-3343	the	_
18-16	3344-3350	CRAFFT	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
18-17	3351-3360	interview	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
18-18	3361-3363	to	_
18-19	3364-3370	assess	_
18-20	3371-3378	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
18-21	3379-3382	and	_
18-22	3383-3392	substance	http://maven.renci.org/NeuroBridge/neurobridge#PsychoactiveSubstanceAbuse
18-23	3393-3396	use	_
18-24	3397-3405	problems	_
18-25	3406-3411	since	_
18-26	3412-3420	baseline	_
18-27	3421-3431	assessment	_
18-28	3432-3433	.	_

19-1	3434-3436	As	_
19-2	3437-3440	the	_
19-3	3441-3444	aim	_
19-4	3445-3447	of	_
19-5	3448-3452	this	_
19-6	3453-3458	study	_
19-7	3459-3462	was	_
19-8	3463-3465	to	_
19-9	3466-3473	examine	_
19-10	3474-3482	baseline	_
19-11	3483-3486	GMV	_
19-12	3487-3489	as	_
19-13	3490-3491	a	_
19-14	3492-3501	predictor	_
19-15	3502-3504	of	_
19-16	3505-3511	future	_
19-17	3512-3519	alcohol	_
19-18	3520-3523	and	_
19-19	3524-3533	substance	_
19-20	3534-3537	use	_
19-21	3538-3546	problems	_
19-22	3547-3548	,	_
19-23	3549-3557	subjects	_
19-24	3558-3562	were	_
19-25	3563-3571	excluded	_
19-26	3572-3574	if	_
19-27	3575-3577	at	_
19-28	3578-3586	baseline	_
19-29	3587-3591	they	_
19-30	3592-3605	self-reported	_
19-31	3606-3610	more	_
19-32	3611-3615	than	_
19-33	3616-3623	minimal	_
19-34	3624-3631	alcohol	_
19-35	3632-3638	and/or	_
19-36	3639-3647	cannabis	_
19-37	3648-3656	exposure	_
19-38	3657-3659	or	_
19-39	3660-3664	ever	_
19-40	3665-3671	having	_
19-41	3672-3676	used	_
19-42	3677-3684	cocaine	_
19-43	3685-3686	,	_
19-44	3687-3694	opioids	_
19-45	3695-3696	,	_
19-46	3697-3710	phencyclidine	_
19-47	3711-3712	,	_
19-48	3713-3726	hallucinogens	_
19-49	3727-3728	,	_
19-50	3729-3731	or	_
19-51	3732-3750	solvents/inhalants	_
19-52	3751-3752	.	_

20-1	3753-3764	Sixty-three	_
20-2	3765-3772	percent	_
20-3	3773-3775	of	_
20-4	3776-3784	subjects	_
20-5	3785-3786	(	_
20-6	3787-3789	11	_
20-7	3790-3795	males	_
20-8	3796-3797	,	_
20-9	3798-3799	8	_
20-10	3800-3807	females	_
20-11	3808-3809	)	_
20-12	3810-3818	reported	_
20-13	3819-3824	never	_
20-14	3825-3831	trying	_
20-15	3832-3839	alcohol	_
20-16	3840-3842	or	_
20-17	3843-3846	any	_
20-18	3847-3852	other	_
20-19	3853-3860	illicit	_
20-20	3861-3871	substances	_
20-21	3872-3874	or	_
20-22	3875-3881	having	_
20-23	3882-3887	tried	_
20-24	3888-3889	a	_
20-25	3890-3893	sip	_
20-26	3894-3896	of	_
20-27	3897-3904	alcohol	_
20-28	3905-3909	once	_
20-29	3910-3912	at	_
20-30	3913-3914	a	_
20-31	3915-3921	family	_
20-32	3922-3931	gathering	_
20-33	3932-3933	.	_

21-1	3934-3943	Remaining	_
21-2	3944-3952	subjects	_
21-3	3953-3961	reported	_
21-4	3962-3968	having	_
21-5	3969-3974	tried	_
21-6	3975-3982	alcohol	_
21-7	3983-3985	or	_
21-8	3986-3994	cannabis	_
21-9	3995-3999	once	_
21-10	4000-4002	or	_
21-11	4003-4005	on	_
21-12	4006-4007	a	_
21-13	4008-4011	few	_
21-14	4012-4021	occasions	_
21-15	4022-4026	with	_
21-16	4027-4032	peers	_
21-17	4033-4034	.	_

22-1	4035-4043	Subjects	_
22-2	4044-4048	were	_
22-3	4049-4052	not	_
22-4	4053-4061	excluded	_
22-5	4062-4065	for	_
22-6	4066-4073	tobacco	_
22-7	4074-4077	use	_
22-8	4078-4079	.	_

23-1	4080-4082	At	_
23-2	4083-4091	baseline	_
23-3	4092-4095	and	_
23-4	4096-4105	follow-up	_
23-5	4106-4116	assessment	_
23-6	4117-4118	,	_
23-7	4119-4126	tobacco	_
23-8	4127-4130	use	_
23-9	4131-4134	was	_
23-10	4135-4143	assessed	_
23-11	4144-4146	as	_
23-12	4147-4154	smoking	_
23-13	4155-4160	using	_
23-14	4161-4164	the	_
23-15	4165-4175	Fagerstrom	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
23-16	4176-4180	Test	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
23-17	4181-4184	for	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
23-18	4185-4193	Nicotine	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
23-19	4194-4204	Dependence	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
23-20	4205-4206	(	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
23-21	4207-4211	FTND	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
23-22	4212-4213	)	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
23-23	4214-4215	.	_

24-1	4216-4218	At	_
24-2	4219-4227	baseline	_
24-3	4228-4229	,	_
24-4	4230-4233	two	_
24-5	4234-4242	subjects	_
24-6	4243-4244	(	_
24-7	4245-4246	7	_
24-8	4247-4248	%	_
24-9	4249-4250	)	_
24-10	4251-4259	reported	_
24-11	4260-4267	current	_
24-12	4268-4275	smoking	_
24-13	4276-4279	and	_
24-14	4280-4283	one	_
24-15	4284-4291	subject	_
24-16	4292-4293	(	_
24-17	4294-4295	3	_
24-18	4296-4297	%	_
24-19	4298-4299	)	_
24-20	4300-4308	reported	_
24-21	4309-4313	past	_
24-22	4314-4321	history	_
24-23	4322-4324	of	_
24-24	4325-4326	,	_
24-25	4327-4330	but	_
24-26	4331-4334	not	_
24-27	4335-4342	current	_
24-28	4343-4344	,	_
24-29	4345-4352	smoking	_
24-30	4353-4354	.	_

25-1	4355-4365	Transition	_
25-2	4366-4368	to	_
25-3	4369-4376	smoking	_
25-4	4377-4380	was	_
25-5	4381-4388	studied	_
25-6	4389-4391	in	_
25-7	4392-4401	remaining	_
25-8	4402-4410	subjects	_
25-9	4411-4412	.	_

26-1	4413-4415	In	_
26-2	4416-4424	addition	_
26-3	4425-4427	to	_
26-4	4428-4431	the	_
26-5	4432-4433	3	_
26-6	4434-4442	subjects	_
26-7	4443-4447	with	_
26-8	4448-4449	a	_
26-9	4450-4457	history	_
26-10	4458-4460	of	_
26-11	4461-4468	smoking	_
26-12	4469-4476	tobacco	_
26-13	4477-4479	at	_
26-14	4480-4488	baseline	_
26-15	4489-4490	,	_
26-16	4491-4493	11	_
26-17	4494-4505	individuals	_
26-18	4506-4507	(	_
26-19	4508-4510	41	_
26-20	4511-4512	%	_
26-21	4513-4514	;	_
26-22	4515-4516	7	_
26-23	4517-4524	females	_
26-24	4525-4526	)	_
26-25	4527-4531	with	_
26-26	4532-4534	no	_
26-27	4535-4542	tobacco	_
26-28	4543-4546	use	_
26-29	4547-4549	at	_
26-30	4550-4558	baseline	_
26-31	4559-4567	reported	_
26-32	4568-4575	history	_
26-33	4576-4578	of	_
26-34	4579-4586	smoking	_
26-35	4587-4589	at	_
26-36	4590-4599	follow-up	_
26-37	4600-4601	(	_
26-38	4602-4603	8	_
26-39	4604-4608	were	_
26-40	4609-4618	currently	_
26-41	4619-4626	smoking	_
26-42	4627-4629	at	_
26-43	4630-4639	follow-up	_
26-44	4640-4650	assessment	_
26-45	4651-4652	;	_
26-46	4653-4654	4	_
26-47	4655-4661	female	_
26-48	4662-4669	current	_
26-49	4670-4677	smokers	_
26-50	4678-4680	at	_
26-51	4681-4690	follow-up	_
26-52	4691-4692	)	_
26-53	4693-4694	.	_

27-1	4695-4702	Sixteen	_
27-2	4703-4714	individuals	_
27-3	4715-4716	(	_
27-4	4717-4719	53	_
27-5	4720-4721	%	_
27-6	4722-4723	;	_
27-7	4724-4725	6	_
27-8	4726-4733	females	_
27-9	4734-4735	)	_
27-10	4736-4744	reported	_
27-11	4745-4747	no	_
27-12	4748-4755	history	_
27-13	4756-4758	of	_
27-14	4759-4766	smoking	_
27-15	4767-4774	tobacco	_
27-16	4775-4777	at	_
27-17	4778-4784	either	_
27-18	4785-4789	time	_
27-19	4790-4795	point	_
27-20	4796-4797	.	_

28-1	4798-4800	On	_
28-2	4801-4804	the	_
28-3	4805-4817	neuroimaging	_
28-4	4818-4821	day	_
28-5	4822-4823	,	_
28-6	4824-4829	urine	_
28-7	4830-4840	toxicology	_
28-8	4841-4848	screens	_
28-9	4849-4852	for	_
28-10	4853-4863	substances	_
28-11	4864-4866	of	_
28-12	4867-4872	abuse	_
28-13	4873-4874	(	_
28-14	4875-4883	cannabis	_
28-15	4884-4885	,	_
28-16	4886-4893	cocaine	_
28-17	4894-4895	,	_
28-18	4896-4907	amphetamine	_
28-19	4908-4909	,	_
28-20	4910-4925	methamphetamine	_
28-21	4926-4927	,	_
28-22	4928-4937	methadone	_
28-23	4938-4939	,	_
28-24	4940-4947	opiates	_
28-25	4948-4949	,	_
28-26	4950-4963	phencyclidine	_
28-27	4964-4965	,	_
28-28	4966-4978	barbiturates	_
28-29	4979-4980	,	_
28-30	4981-4984	and	_
28-31	4985-5000	benzodiazepines	_
28-32	5001-5002	)	_
28-33	5003-5007	were	_
28-34	5008-5016	negative	_
28-35	5017-5020	for	_
28-36	5021-5024	all	_
28-37	5025-5033	subjects	_
28-38	5034-5035	.	_

29-1	5036-5045	Exclusion	_
29-2	5046-5054	criteria	_
29-3	5055-5063	included	_
29-4	5064-5071	history	_
29-5	5072-5074	of	_
29-6	5075-5087	neurological	_
29-7	5088-5095	illness	_
29-8	5096-5097	,	_
29-9	5098-5107	including	_
29-10	5108-5112	head	_
29-11	5113-5119	trauma	_
29-12	5120-5124	with	_
29-13	5125-5129	loss	_
29-14	5130-5132	of	_
29-15	5133-5146	consciousness	_
29-16	5147-5150	for	_
29-17	5151-5156	≥5min	_
29-18	5157-5158	,	_
29-19	5159-5161	or	_
29-20	5162-5167	major	_
29-21	5168-5175	medical	_
29-22	5176-5183	illness	_
29-23	5184-5185	.	_

30-1	5186-5194	Subjects	_
30-2	5195-5199	were	_
30-3	5200-5203	not	_
30-4	5204-5212	excluded	_
30-5	5213-5216	for	_
30-6	5217-5230	comorbidities	_
30-7	5231-5233	or	_
30-8	5234-5240	family	_
30-9	5241-5248	history	_
30-10	5249-5251	of	_
30-11	5252-5263	psychiatric	_
30-12	5264-5273	disorders	_
30-13	5274-5276	as	_
30-14	5277-5282	there	_
30-15	5283-5286	are	_
30-16	5287-5291	high	_
30-17	5292-5297	rates	_
30-18	5298-5300	of	_
30-19	5301-5306	these	_
30-20	5307-5309	in	_
30-21	5310-5321	individuals	_
30-22	5322-5326	with	_
30-23	5327-5329	BD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
30-24	5330-5333	and	_
30-25	5334-5343	excluding	_
30-26	5344-5353	decreases	_
30-27	5354-5370	generalizability	_
30-28	5371-5372	.	_

31-1	5373-5378	After	_
31-2	5379-5387	complete	_
31-3	5388-5399	description	_
31-4	5400-5402	of	_
31-5	5403-5406	the	_
31-6	5407-5412	study	_
31-7	5413-5414	,	_
31-8	5415-5422	written	_
31-9	5423-5431	informed	_
31-10	5432-5439	consent	_
31-11	5440-5443	was	_
31-12	5444-5452	obtained	_
31-13	5453-5457	from	_
31-14	5458-5466	subjects	_
31-15	5467-5470	≥18	_
31-16	5471-5476	years	_
31-17	5477-5478	,	_
31-18	5479-5482	and	_
31-19	5483-5489	assent	_
31-20	5490-5493	and	_
31-21	5494-5509	parent/guardian	_
31-22	5510-5520	permission	_
31-23	5521-5525	from	_
31-24	5526-5534	subjects	_
31-25	5535-5536	<	_
31-26	5537-5539	18	_
31-27	5540-5541	,	_
31-28	5542-5544	in	_
31-29	5545-5555	accordance	_
31-30	5556-5560	with	_
31-31	5561-5564	the	_
31-32	5565-5569	Yale	_
31-33	5570-5576	School	_
31-34	5577-5579	of	_
31-35	5580-5588	Medicine	_
31-36	5589-5594	human	_
31-37	5595-5608	investigation	_
31-38	5609-5618	committee	_
31-39	5619-5620	.	_

32-1	5621-5624	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
32-2	5625-5636	Acquisition	_
32-3	5637-5640	and	_
32-4	5641-5651	Processing	_
32-5	5652-5667	High-resolution	_
32-6	5668-5672	sMRI	http://maven.renci.org/NeuroBridge/neurobridge#Thing
32-7	5673-5677	data	_
32-8	5678-5682	were	_
32-9	5683-5691	acquired	_
32-10	5692-5695	for	_
32-11	5696-5700	each	_
32-12	5701-5708	subject	_
32-13	5709-5713	with	_
32-14	5714-5715	a	_
32-15	5716-5723	3-Tesla	_
32-16	5724-5731	Siemens	_
32-17	5732-5736	Trio	_
32-18	5737-5739	MR	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
32-19	5740-5747	scanner	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
32-20	5748-5749	(	_
32-21	5750-5757	Siemens	_
32-22	5758-5759	,	_
32-23	5760-5768	Erlangen	_
32-24	5769-5770	,	_
32-25	5771-5778	Germany	_
32-26	5779-5780	)	_
32-27	5781-5782	.	_

33-1	5783-5786	The	_
33-2	5787-5791	sMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
33-3	5792-5800	sagittal	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
33-4	5801-5807	images	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
33-5	5808-5812	were	_
33-6	5813-5821	acquired	_
33-7	5822-5826	with	_
33-8	5827-5828	a	_
33-9	5829-5846	three-dimensional	_
33-10	5847-5860	magnetization	_
33-11	5861-5869	prepared	_
33-12	5870-5875	rapid	_
33-13	5876-5887	acquisition	http://maven.renci.org/NeuroBridge/neurobridge#Intervention
33-14	5888-5896	gradient	http://maven.renci.org/NeuroBridge/neurobridge#Intervention
33-15	5897-5901	echo	http://maven.renci.org/NeuroBridge/neurobridge#Intervention
33-16	5902-5903	(	http://maven.renci.org/NeuroBridge/neurobridge#Intervention
33-17	5904-5910	MPRAGE	http://maven.renci.org/NeuroBridge/neurobridge#Intervention
33-18	5911-5912	)	http://maven.renci.org/NeuroBridge/neurobridge#Intervention
33-19	5913-5924	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
33-20	5925-5933	sequence	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
33-21	5934-5938	with	_
33-22	5939-5949	parameters	_
33-23	5950-5951	:	_
33-24	5952-5962	repetition	_
33-25	5963-5967	time	_
33-26	5968-5969	(	_
33-27	5970-5972	TR	_
33-28	5973-5974	)	_
33-29	5975-5982	=1500ms	_
33-30	5983-5984	,	_
33-31	5985-5989	echo	_
33-32	5990-5994	time	_
33-33	5995-5996	(	_
33-34	5997-5999	TE	_
33-35	6000-6001	)	_
33-36	6002-6009	=2.83ms	_
33-37	6010-6011	,	_
33-38	6012-6018	matrix	_
33-39	6019-6022	256	_
33-40	6023-6024	×	_
33-41	6025-6028	256	_
33-42	6029-6030	,	_
33-43	6031-6036	field	_
33-44	6037-6039	of	_
33-45	6040-6044	view	_
33-46	6045-6046	(	_
33-47	6047-6050	FOV	_
33-48	6051-6052	)	_
33-49	6053-6059	=256mm	_
33-50	6060-6061	x	_
33-51	6062-6068	256mm2	_
33-52	6069-6070	,	_
33-53	6071-6074	and	_
33-54	6075-6078	160	_
33-55	6079-6085	one-mm	_
33-56	6086-6092	slices	_
33-57	6093-6100	without	_
33-58	6101-6104	gap	_
33-59	6105-6108	and	_
33-60	6109-6112	two	_
33-61	6113-6121	averages	_
33-62	6122-6123	.	_

34-1	6124-6130	Images	_
34-2	6131-6135	were	_
34-3	6136-6145	processed	_
34-4	6146-6150	with	_
34-5	6151-6154	the	_
34-6	6155-6161	DARTEL	_
34-7	6162-6169	toolbox	_
34-8	6170-6176	within	_
34-9	6177-6188	Statistical	_
34-10	6189-6192	and	_
34-11	6193-6203	Parametric	_
34-12	6204-6211	Mapping	_
34-13	6212-6214	12	_
34-14	6215-6216	(	_
34-15	6217-6222	SPM12	_
34-16	6223-6224	)	_
34-17	6225-6226	(	_
34-18	6227-6231	http	_
34-19	6232-6233	:	_
34-20	6234-6261	//www.fil.ion.ucl.ac.uk/spm	_
34-21	6262-6263	)	_
34-22	6264-6265	.	_

35-1	6266-6269	The	_
35-2	6270-6273	SPM	_
35-3	6274-6286	segmentation	_
35-4	6287-6295	function	_
35-5	6296-6299	and	_
35-6	6300-6303	SPM	_
35-7	6304-6310	tissue	_
35-8	6311-6322	probability	_
35-9	6323-6327	maps	_
35-10	6328-6331	for	_
35-11	6332-6336	gray	_
35-12	6337-6343	matter	_
35-13	6344-6345	,	_
35-14	6346-6351	white	_
35-15	6352-6358	matter	_
35-16	6359-6362	and	_
35-17	6363-6371	cerebral	_
35-18	6372-6378	spinal	_
35-19	6379-6384	fluid	_
35-20	6385-6389	were	_
35-21	6390-6401	implemented	_
35-22	6402-6405	for	_
35-23	6406-6410	bias	_
35-24	6411-6421	correction	_
35-25	6422-6425	and	_
35-26	6426-6438	segmentation	_
35-27	6439-6442	and	_
35-28	6443-6447	used	_
35-29	6448-6450	to	_
35-30	6451-6457	create	_
35-31	6458-6464	DARTEL	_
35-32	6465-6474	templates	_
35-33	6475-6480	using	_
35-34	6481-6484	the	_
35-35	6485-6486	“	_
35-36	6487-6490	Run	_
35-37	6491-6497	Dartel	_
35-38	6498-6499	(	_
35-39	6500-6506	create	_
35-40	6507-6516	Templates	_
35-41	6517-6518	)	_
35-42	6519-6520	”	_
35-43	6521-6528	command	_
35-44	6529-6534	under	_
35-45	6535-6541	DARTEL	_
35-46	6542-6547	tools	_
35-47	6548-6549	.	_

36-1	6550-6554	Data	_
36-2	6555-6559	were	_
36-3	6560-6570	normalized	_
36-4	6571-6573	to	_
36-5	6574-6582	Montreal	_
36-6	6583-6595	Neurological	_
36-7	6596-6605	Institute	_
36-8	6606-6607	(	_
36-9	6608-6611	MNI	_
36-10	6612-6613	)	_
36-11	6614-6619	space	_
36-12	6620-6623	and	_
36-13	6624-6632	smoothed	_
36-14	6633-6637	with	_
36-15	6638-6640	an	_
36-16	6641-6644	8mm	_
36-17	6645-6671	full-width-at-half-maximum	_
36-18	6672-6673	(	_
36-19	6674-6678	FWHM	_
36-20	6679-6680	)	_
36-21	6681-6690	isotropic	_
36-22	6691-6697	kernel	_
36-23	6698-6699	.	_

37-1	6700-6707	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale
37-2	6708-6711	and	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale
37-3	6712-6721	Substance	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale
37-4	6722-6725	Use	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale
37-5	6726-6734	Subjects	_
37-6	6735-6739	were	_
37-7	6740-6752	administered	_
37-8	6753-6756	the	_
37-9	6757-6763	CRAFFT	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
37-10	6764-6773	interview	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
37-11	6774-6775	,	_
37-12	6776-6781	which	_
37-13	6782-6790	consists	_
37-14	6791-6793	of	_
37-15	6794-6795	6	_
37-16	6796-6802	yes/no	_
37-17	6803-6812	questions	_
37-18	6813-6822	inquiring	_
37-19	6823-6828	about	_
37-20	6829-6833	risk	_
37-21	6834-6844	indicators	_
37-22	6845-6847	or	_
37-23	6848-6856	problems	_
37-24	6857-6868	experienced	_
37-25	6869-6873	from	_
37-26	6874-6881	alcohol	_
37-27	6882-6884	or	_
37-28	6885-6889	drug	_
37-29	6890-6893	use	_
37-30	6894-6895	.	_

38-1	6896-6902	CRAFFT	_
38-2	6903-6905	is	_
38-3	6906-6908	an	_
38-4	6909-6916	acronym	_
38-5	6917-6921	with	_
38-6	6922-6926	each	_
38-7	6927-6933	letter	_
38-8	6934-6946	representing	_
38-9	6947-6950	one	_
38-10	6951-6953	of	_
38-11	6954-6955	6	_
38-12	6956-6961	items	_
38-13	6962-6963	.	_

39-1	6964-6965	C	_
39-2	6966-6973	relates	_
39-3	6974-6976	to	_
39-4	6977-6984	history	_
39-5	6985-6987	of	_
39-6	6988-6995	driving	_
39-7	6996-6998	or	_
39-8	6999-7005	riding	_
39-9	7006-7008	in	_
39-10	7009-7010	a	_
39-11	7011-7014	Car	_
39-12	7015-7021	driven	_
39-13	7022-7024	by	_
39-14	7025-7032	someone	_
39-15	7033-7036	who	_
39-16	7037-7040	had	_
39-17	7041-7045	been	_
39-18	7046-7051	using	_
39-19	7052-7065	alcohol/drugs	_
39-20	7066-7067	,	_
39-21	7068-7069	R	_
39-22	7070-7072	if	_
39-23	7073-7077	used	_
39-24	7078-7091	alcohol/drugs	_
39-25	7092-7094	to	_
39-26	7095-7100	Relax	_
39-27	7101-7102	,	_
39-28	7103-7104	A	_
39-29	7105-7107	if	_
39-30	7108-7112	used	_
39-31	7113-7126	alcohol/drugs	_
39-32	7127-7132	while	_
39-33	7133-7138	Alone	_
39-34	7139-7140	,	_
39-35	7141-7142	F	_
39-36	7143-7145	if	_
39-37	7146-7155	Forgotten	_
39-38	7156-7162	things	_
39-39	7163-7166	one	_
39-40	7167-7170	did	_
39-41	7171-7176	while	_
39-42	7177-7182	using	_
39-43	7183-7196	alcohol/drugs	_
39-44	7197-7198	,	_
39-45	7199-7200	F	_
39-46	7201-7208	whether	_
39-47	7209-7213	told	_
39-48	7214-7216	by	_
39-49	7217-7231	Family/Friends	_
39-50	7232-7234	to	_
39-51	7235-7238	cut	_
39-52	7239-7243	down	_
39-53	7244-7246	on	_
39-54	7247-7259	alcohol/drug	_
39-55	7260-7263	use	_
39-56	7264-7265	,	_
39-57	7266-7269	and	_
39-58	7270-7271	T	_
39-59	7272-7279	whether	_
39-60	7280-7286	gotten	_
39-61	7287-7291	into	_
39-62	7292-7299	Trouble	_
39-63	7300-7305	while	_
39-64	7306-7311	using	_
39-65	7312-7325	alcohol/drugs	_
39-66	7326-7327	.	_

40-1	7328-7331	The	_
40-2	7332-7341	questions	_
40-3	7342-7345	are	_
40-4	7346-7353	equally	_
40-5	7354-7362	weighted	_
40-6	7363-7364	(	_
40-7	7365-7368	one	_
40-8	7369-7374	point	_
40-9	7375-7378	for	_
40-10	7379-7383	each	_
40-11	7384-7387	yes	_
40-12	7388-7394	answer	_
40-13	7395-7396	)	_
40-14	7397-7398	.	_

41-1	7399-7402	The	_
41-2	7403-7409	CRAFFT	_
41-3	7410-7413	has	_
41-4	7414-7425	substantial	_
41-5	7426-7435	empirical	_
41-6	7436-7443	support	_
41-7	7444-7446	as	_
41-8	7447-7448	a	_
41-9	7449-7458	substance	_
41-10	7459-7462	use	_
41-11	7463-7472	screening	_
41-12	7473-7483	instrument	_
41-13	7484-7487	for	_
41-14	7488-7499	adolescents	_
41-15	7500-7502	in	_
41-16	7503-7511	multiple	_
41-17	7512-7520	settings	_
41-18	7521-7522	,	_
41-19	7523-7532	including	_
41-20	7533-7543	outpatient	_
41-21	7544-7551	general	_
41-22	7552-7559	medical	_
41-23	7560-7563	and	_
41-24	7564-7573	inpatient	_
41-25	7574-7585	psychiatric	_
41-26	7586-7594	settings	_
41-27	7595-7596	.	_

42-1	7597-7598	A	_
42-2	7599-7604	score	_
42-3	7605-7607	of	_
42-4	7608-7610	≥2	_
42-5	7611-7614	has	_
42-6	7615-7619	been	_
42-7	7620-7624	used	_
42-8	7625-7627	as	_
42-9	7628-7631	the	_
42-10	7632-7641	threshold	_
42-11	7642-7649	optimal	_
42-12	7650-7653	for	_
42-13	7654-7665	identifying	_
42-14	7666-7683	alcohol/substance	_
42-15	7684-7692	problems	_
42-16	7693-7694	.	_

43-1	7695-7697	At	_
43-2	7698-7707	follow-up	_
43-3	7708-7709	,	_
43-4	7710-7712	19	_
43-5	7713-7714	(	_
43-6	7715-7717	63	_
43-7	7718-7719	%	_
43-8	7720-7721	)	_
43-9	7722-7734	participants	_
43-10	7735-7738	had	_
43-11	7739-7740	a	_
43-12	7741-7747	CRAFFT	_
43-13	7748-7753	score	_
43-14	7754-7756	of	_
43-15	7757-7759	≥2	_
43-16	7760-7761	(	_
43-17	7762-7776	CRAFFTmean+SD=	_
43-18	7777-7784	2.3+2.1	_
43-19	7785-7786	;	_
43-20	7787-7793	scores	_
43-21	7794-7800	ranged	_
43-22	7801-7805	from	_
43-23	7806-7809	0–6	_
43-24	7810-7813	and	_
43-25	7814-7820	showed	_
43-26	7821-7822	a	_
43-27	7823-7829	normal	_
43-28	7830-7842	distribution	_
43-29	7843-7845	in	_
43-30	7846-7850	both	_
43-31	7851-7856	males	_
43-32	7857-7860	and	_
43-33	7861-7868	females	_
43-34	7869-7870	)	_
43-35	7871-7872	.	_

44-1	7873-7883	Additional	_
44-2	7884-7895	Assessments	_
44-3	7896-7908	Participants	_
44-4	7909-7913	were	_
44-5	7914-7922	assessed	_
44-6	7923-7927	with	_
44-7	7928-7931	the	_
44-8	7932-7937	Young	http://maven.renci.org/NeuroBridge/neurobridge#YoungManiaRatingScale
44-9	7938-7943	Mania	http://maven.renci.org/NeuroBridge/neurobridge#YoungManiaRatingScale
44-10	7944-7950	Rating	http://maven.renci.org/NeuroBridge/neurobridge#YoungManiaRatingScale
44-11	7951-7956	Scale	http://maven.renci.org/NeuroBridge/neurobridge#YoungManiaRatingScale
44-12	7957-7960	and	_
44-13	7961-7964	the	_
44-14	7965-7974	2-subtest	_
44-15	7975-7982	version	_
44-16	7983-7984	(	_
44-17	7985-7991	Matrix	_
44-18	7992-8001	Reasoning	http://maven.renci.org/NeuroBridge/neurobridge#PhysicalMeasurement
44-19	8002-8005	and	http://maven.renci.org/NeuroBridge/neurobridge#PhysicalMeasurement
44-20	8006-8016	Vocabulary	_
44-21	8017-8018	)	http://maven.renci.org/NeuroBridge/neurobridge#Thing
44-22	8019-8021	of	_
44-23	8022-8025	the	_
44-24	8026-8034	Weschler	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
44-25	8035-8046	Abbreviated	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
44-26	8047-8053	Scales	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
44-27	8054-8056	of	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
44-28	8057-8069	Intelligence	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
44-29	8070-8071	.	_

45-1	8072-8084	Additionally	_
45-2	8085-8086	,	_
45-3	8087-8089	at	_
45-4	8090-8098	baseline	_
45-5	8099-8109	assessment	_
45-6	8110-8111	,	_
45-7	8112-8114	27	_
45-8	8115-8127	participants	_
45-9	8128-8129	[	_
45-10	8130-8132	14	_
45-11	8133-8139	female	_
45-12	8140-8141	(	_
45-13	8142-8144	51	_
45-14	8145-8146	%	_
45-15	8147-8148	)	_
45-16	8149-8150	]	_
45-17	8151-8160	completed	_
45-18	8161-8164	the	_
45-19	8165-8170	Child	http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale
45-20	8171-8181	Depression	http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale
45-21	8182-8188	Rating	http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale
45-22	8189-8194	Scale	http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale
45-23	8195-8196	(	http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale
45-24	8197-8201	CDRS	http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale
45-25	8202-8203	)	http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale
45-26	8204-8207	and	_
45-27	8208-8210	25	_
45-28	8211-8223	participants	_
45-29	8224-8225	[	_
45-30	8226-8228	12	_
45-31	8229-8235	female	_
45-32	8236-8237	(	_
45-33	8238-8240	48	_
45-34	8241-8242	%	_
45-35	8243-8244	)	_
45-36	8245-8246	]	_
45-37	8247-8250	the	_
45-38	8251-8258	Barratt	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
45-39	8259-8272	Impulsiveness	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
45-40	8273-8278	Scale	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
45-41	8279-8280	(	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
45-42	8281-8284	BIS	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
45-43	8285-8286	)	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
45-44	8287-8290	-11	_
45-45	8291-8293	or	_
45-46	8294-8301	BIS-11a	_
45-47	8302-8303	.	_

46-1	8304-8307	The	_
46-2	8308-8311	BIS	_
46-3	8312-8314	is	_
46-4	8315-8316	a	_
46-5	8317-8330	self-reported	_
46-6	8331-8338	measure	_
46-7	8339-8341	of	_
46-8	8342-8347	trait	_
46-9	8348-8359	impulsivity	_
46-10	8360-8361	.	_

47-1	8362-8365	The	_
47-2	8366-8371	total	_
47-3	8372-8375	BIS	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
47-4	8376-8381	score	_
47-5	8382-8384	is	_
47-6	8385-8388	the	_
47-7	8389-8392	sum	_
47-8	8393-8395	of	_
47-9	8396-8401	three	_
47-10	8402-8410	subscale	_
47-11	8411-8417	scores	_
47-12	8418-8419	:	_
47-13	8420-8432	non-planning	_
47-14	8433-8444	impulsivity	_
47-15	8445-8446	,	_
47-16	8447-8468	cognitive-attentional	_
47-17	8469-8480	impulsivity	_
47-18	8481-8482	,	_
47-19	8483-8486	and	_
47-20	8487-8492	motor	_
47-21	8493-8504	impulsivity	_
47-22	8505-8506	.	_

48-1	8507-8514	BIS-11a	_
48-2	8515-8521	scores	_
48-3	8522-8526	were	_
48-4	8527-8535	prorated	_
48-5	8536-8538	to	_
48-6	8539-8545	BIS-11	_
48-7	8546-8552	scores	_
48-8	8553-8555	as	_
48-9	8556-8566	previously	_
48-10	8567-8576	described	_
48-11	8577-8578	.	_

49-1	8579-8590	Statistical	_
49-2	8591-8599	Analyses	_
49-3	8600-8611	Demographic	_
49-4	8612-8615	and	_
49-5	8616-8624	Clinical	_
49-6	8625-8632	Feature	_
49-7	8633-8641	Analysis	_
49-8	8642-8650	Subjects	_
49-9	8651-8655	were	_
49-10	8656-8667	categorized	_
49-11	8668-8672	into	_
49-12	8673-8678	those	_
49-13	8679-8686	scoring	_
49-14	8687-8689	at	_
49-15	8690-8694	high	_
49-16	8695-8696	(	_
49-17	8697-8698	>	_
49-18	8699-8700	2	_
49-19	8701-8702	:	_
49-20	8703-8713	CRAFFTHIGH	_
49-21	8714-8715	)	_
49-22	8716-8722	versus	_
49-23	8723-8726	low	_
49-24	8727-8728	(	_
49-25	8729-8730	<	_
49-26	8731-8732	2	_
49-27	8733-8734	:	_
49-28	8735-8744	CRAFFTLOW	_
49-29	8745-8746	)	_
49-30	8747-8751	risk	_
49-31	8752-8755	for	_
49-32	8756-8763	alcohol	_
49-33	8764-8767	and	_
49-34	8768-8777	substance	_
49-35	8778-8781	use	_
49-36	8782-8790	problems	_
49-37	8791-8792	.	_

50-1	8793-8804	Independent	_
50-2	8805-8812	t-tests	_
50-3	8813-8817	were	_
50-4	8818-8827	performed	_
50-5	8828-8830	to	_
50-6	8831-8837	assess	_
50-7	8838-8843	group	_
50-8	8844-8855	differences	_
50-9	8856-8858	in	_
50-10	8859-8862	age	_
50-11	8863-8865	at	_
50-12	8866-8874	baseline	_
50-13	8875-8880	scans	_
50-14	8881-8882	,	_
50-15	8883-8886	age	_
50-16	8887-8889	at	_
50-17	8890-8899	follow-up	_
50-18	8900-8901	,	_
50-19	8902-8910	interval	_
50-20	8911-8918	between	_
50-21	8919-8927	baseline	_
50-22	8928-8932	scan	_
50-23	8933-8936	and	_
50-24	8937-8946	follow-up	_
50-25	8947-8948	,	_
50-26	8949-8952	and	_
50-27	8953-8961	baseline	_
50-28	8962-8964	IQ	_
50-29	8965-8966	,	_
50-30	8967-8972	years	_
50-31	8973-8975	of	_
50-32	8976-8985	education	_
50-33	8986-8987	,	_
50-34	8988-8993	Young	_
50-35	8994-8999	Mania	_
50-36	9000-9006	Rating	http://maven.renci.org/NeuroBridge/neurobridge#RatingScale
50-37	9007-9012	Scale	http://maven.renci.org/NeuroBridge/neurobridge#RatingScale
50-38	9013-9014	,	_
50-39	9015-9019	CDRS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
50-40	9020-9023	and	_
50-41	9024-9027	BIS	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
50-42	9028-9029	(	_
50-43	9030-9035	total	_
50-44	9036-9039	and	_
50-45	9040-9048	subscale	_
50-46	9049-9050	)	_
50-47	9051-9057	scores	_
50-48	9058-9059	.	_

51-1	9060-9070	Chi-square	_
51-2	9071-9072	(	_
51-3	9073-9075	or	_
51-4	9076-9082	Fisher	_
51-5	9083-9084	’	_
51-6	9085-9086	s	_
51-7	9087-9092	exact	_
51-8	9093-9094	)	_
51-9	9095-9100	tests	_
51-10	9101-9105	were	_
51-11	9106-9110	used	_
51-12	9111-9113	to	_
51-13	9114-9121	examine	_
51-14	9122-9129	whether	_
51-15	9130-9138	clinical	_
51-16	9139-9146	factors	_
51-17	9147-9155	differed	_
51-18	9156-9158	by	_
51-19	9159-9165	CRAFFT	_
51-20	9166-9171	group	_
51-21	9172-9174	at	_
51-22	9175-9183	baseline	_
51-23	9184-9185	(	_
51-24	9186-9189	see	_
51-25	9190-9195	Table	_
51-26	9196-9197	2	_
51-27	9198-9201	and	_
51-28	9202-9207	Table	_
51-29	9208-9209	3	_
51-30	9210-9211	)	_
51-31	9212-9213	.	_

52-1	9214-9219	These	_
52-2	9220-9228	included	_
52-3	9229-9233	mood	_
52-4	9234-9239	state	_
52-5	9240-9241	(	_
52-6	9242-9250	euthymic	_
52-7	9251-9252	,	_
52-8	9253-9262	depressed	_
52-9	9263-9264	,	_
52-10	9265-9273	elevated	_
52-11	9274-9275	)	_
52-12	9276-9277	,	_
52-13	9278-9285	history	_
52-14	9286-9287	(	_
52-15	9288-9294	yes/no	_
52-16	9295-9296	)	_
52-17	9297-9299	of	_
52-18	9300-9315	hospitalization	_
52-19	9316-9317	,	_
52-20	9318-9323	rapid	_
52-21	9324-9331	cycling	_
52-22	9332-9333	,	_
52-23	9334-9343	psychosis	_
52-24	9344-9345	,	_
52-25	9346-9353	suicide	_
52-26	9354-9361	attempt	_
52-27	9362-9363	,	_
52-28	9364-9371	smoking	_
52-29	9372-9379	tobacco	_
52-30	9380-9381	,	_
52-31	9382-9390	comorbid	_
52-32	9391-9400	diagnosis	_
52-33	9401-9402	(	_
52-34	9403-9409	yes/no	_
52-35	9410-9411	)	_
52-36	9412-9414	of	_
52-37	9415-9430	simple/specific	_
52-38	9431-9437	phobia	_
52-39	9438-9439	,	_
52-40	9440-9444	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
52-41	9445-9446	,	_
52-42	9447-9450	ODD	http://maven.renci.org/NeuroBridge/neurobridge#MoodDisorder
52-43	9451-9452	,	_
52-44	9453-9455	CD	_
52-45	9456-9457	,	_
52-46	9458-9460	or	_
52-47	9461-9471	separation	_
52-48	9472-9479	anxiety	_
52-49	9480-9481	,	_
52-50	9482-9485	and	_
52-51	9486-9496	medication	_
52-52	9497-9507	subclasses	_
52-53	9508-9509	(	_
52-54	9510-9516	on/off	_
52-55	9517-9518	)	_
52-56	9519-9520	.	_

53-1	9521-9529	Analyses	_
53-2	9530-9534	were	_
53-3	9535-9543	repeated	_
53-4	9544-9554	stratified	_
53-5	9555-9557	by	_
53-6	9558-9561	sex	_
53-7	9562-9563	.	_

54-1	9564-9576	Additionally	_
54-2	9577-9578	,	_
54-3	9579-9580	a	_
54-4	9581-9591	Chi-square	_
54-5	9592-9596	test	_
54-6	9597-9600	was	_
54-7	9601-9605	used	_
54-8	9606-9608	to	_
54-9	9609-9615	assess	_
54-10	9616-9618	if	_
54-11	9619-9622	the	_
54-12	9623-9629	number	_
54-13	9630-9632	of	_
54-14	9633-9644	individuals	_
54-15	9645-9658	transitioning	_
54-16	9659-9661	to	_
54-17	9662-9669	smoking	_
54-18	9670-9677	tobacco	_
54-19	9678-9685	between	_
54-20	9686-9694	baseline	_
54-21	9695-9698	and	_
54-22	9699-9708	follow-up	_
54-23	9709-9719	assessment	_
54-24	9720-9728	differed	_
54-25	9729-9731	by	_
54-26	9732-9738	CRAFFT	_
54-27	9739-9744	group	_
54-28	9745-9746	(	_
54-29	9747-9756	excluding	_
54-30	9757-9758	3	_
54-31	9759-9770	individuals	_
54-32	9771-9775	with	_
54-33	9776-9784	baseline	_
54-34	9785-9792	history	_
54-35	9793-9795	of	_
54-36	9796-9803	tobacco	_
54-37	9804-9807	use	_
54-38	9808-9809	)	_
54-39	9810-9811	.	_

55-1	9812-9813	A	_
55-2	9814-9820	Fisher	_
55-3	9821-9822	’	_
55-4	9823-9824	s	_
55-5	9825-9830	exact	_
55-6	9831-9835	test	_
55-7	9836-9839	was	_
55-8	9840-9844	used	_
55-9	9845-9847	to	_
55-10	9848-9854	assess	_
55-11	9855-9862	whether	_
55-12	9863-9873	CRAFFTHIGH	_
55-13	9874-9879	males	_
55-14	9880-9883	and	_
55-15	9884-9891	females	_
55-16	9892-9900	differed	_
55-17	9901-9903	in	_
55-18	9904-9907	the	_
55-19	9908-9914	number	_
55-20	9915-9917	of	_
55-21	9918-9929	individuals	_
55-22	9930-9933	who	_
55-23	9934-9946	transitioned	_
55-24	9947-9949	to	_
55-25	9950-9957	smoking	_
55-26	9958-9965	tobacco	_
55-27	9966-9973	between	_
55-28	9974-9982	baseline	_
55-29	9983-9986	and	_
55-30	9987-9996	follow-up	_
55-31	9997-10007	assessment	_
55-32	10008-10009	.	_

56-1	10010-10017	Results	_
56-2	10018-10022	were	_
56-3	10023-10033	considered	_
56-4	10034-10045	significant	_
56-5	10046-10048	at	_
56-6	10049-10050	p	_
56-7	10051-10052	<	_
56-8	10053-10057	0.05	_
56-9	10058-10059	.	_

57-1	10060-10063	SPM	_
57-2	10064-10075	Voxel-Based	_
57-3	10076-10084	Analysis	_
57-4	10085-10086	A	_
57-5	10087-10097	two-sample	_
57-6	10098-10104	t-test	_
57-7	10105-10108	was	_
57-8	10109-10118	conducted	_
57-9	10119-10121	in	_
57-10	10122-10127	SPM12	_
57-11	10128-10130	to	_
57-12	10131-10137	assess	_
57-13	10138-10148	CRAFFTHIGH	_
57-14	10149-10155	versus	_
57-15	10156-10165	CRAFFTLOW	_
57-16	10166-10171	group	_
57-17	10172-10183	differences	_
57-18	10184-10186	in	_
57-19	10187-10195	baseline	_
57-20	10196-10199	GMV	_
57-21	10200-10201	,	_
57-22	10202-10211	including	_
57-23	10212-10216	data	_
57-24	10217-10221	from	_
57-25	10222-10225	all	_
57-26	10226-10234	subjects	_
57-27	10235-10236	.	_

58-1	10237-10240	For	_
58-2	10241-10253	hypothesized	_
58-3	10254-10261	regions	_
58-4	10262-10263	,	_
58-5	10264-10267	PFC	_
58-6	10268-10269	,	_
58-7	10270-10277	insular	_
58-8	10278-10281	and	_
58-9	10282-10294	temporopolar	_
58-10	10295-10303	cortices	_
58-11	10304-10307	and	_
58-12	10308-10316	amygdala	_
58-13	10317-10318	,	_
58-14	10319-10326	results	_
58-15	10327-10331	were	_
58-16	10332-10342	considered	_
58-17	10343-10354	significant	_
58-18	10355-10357	at	_
58-19	10358-10359	p	_
58-20	10360-10361	<	_
58-21	10362-10367	0.005	_
58-22	10368-10369	(	_
58-23	10370-10381	uncorrected	_
58-24	10382-10383	)	_
58-25	10384-10387	and	_
58-26	10388-10396	clusters	_
58-27	10397-10398	>	_
58-28	10399-10401	20	_
58-29	10402-10408	voxels	_
58-30	10409-10410	.	_

59-1	10411-10415	This	_
59-2	10416-10425	threshold	_
59-3	10426-10429	was	_
59-4	10430-10436	chosen	_
59-5	10437-10439	to	_
59-6	10440-10447	balance	_
59-7	10448-10451	for	_
59-8	10452-10456	type	_
59-9	10457-10458	I	_
59-10	10459-10462	and	_
59-11	10463-10467	type	_
59-12	10468-10470	II	_
59-13	10471-10477	errors	_
59-14	10478-10480	in	_
59-15	10481-10492	preliminary	_
59-16	10493-10500	studies	_
59-17	10501-10502	.	_

60-1	10503-10506	For	_
60-2	10507-10516	remaining	_
60-3	10517-10522	brain	_
60-4	10523-10530	regions	_
60-5	10531-10532	,	_
60-6	10533-10541	findings	_
60-7	10542-10546	were	_
60-8	10547-10557	considered	_
60-9	10558-10560	as	_
60-10	10561-10572	significant	_
60-11	10573-10577	with	_
60-12	10578-10579	p	_
60-13	10580-10581	<	_
60-14	10582-10586	0.05	_
60-15	10587-10598	Family-Wise	_
60-16	10599-10604	Error	_
60-17	10605-10606	(	_
60-18	10607-10610	FWE	_
60-19	10611-10612	)	_
60-20	10613-10623	-corrected	_
60-21	10624-10627	and	_
60-22	10628-10629	a	_
60-23	10630-10639	threshold	_
60-24	10640-10642	of	_
60-25	10643-10645	10	_
60-26	10646-10652	voxels	_
60-27	10653-10656	for	_
60-28	10657-10665	multiple	_
60-29	10666-10677	comparisons	_
60-30	10678-10679	.	_

61-1	10680-10684	Mean	_
61-2	10685-10688	GMV	_
61-3	10689-10690	,	_
61-4	10691-10700	extracted	_
61-5	10701-10705	from	_
61-6	10706-10714	clusters	_
61-7	10715-10722	showing	_
61-8	10723-10734	significant	_
61-9	10735-10746	differences	_
61-10	10747-10754	between	_
61-11	10755-10761	CRAFFT	_
61-12	10762-10768	groups	_
61-13	10769-10770	,	_
61-14	10771-10775	were	_
61-15	10776-10786	calculated	_
61-16	10787-10788	.	_

62-1	10789-10793	Post	_
62-2	10794-10797	hoc	_
62-3	10798-10806	analysis	_
62-4	10807-10810	was	_
62-5	10811-10820	performed	_
62-6	10821-10823	to	_
62-7	10824-10830	assess	_
62-8	10831-10837	effect	_
62-9	10838-10840	of	_
62-10	10841-10847	CRAFFT	_
62-11	10848-10853	group	_
62-12	10854-10858	when	_
62-13	10859-10868	covarying	_
62-14	10869-10872	age	_
62-15	10873-10875	or	_
62-16	10876-10878	IQ	_
62-17	10879-10881	at	_
62-18	10882-10890	baseline	_
62-19	10891-10892	,	_
62-20	10893-10897	with	_
62-21	10898-10901	GMV	_
62-22	10902-10906	from	_
62-23	10907-10916	extracted	_
62-24	10917-10925	clusters	_
62-25	10926-10928	as	_
62-26	10929-10932	the	_
62-27	10933-10942	dependent	_
62-28	10943-10952	variables	_
62-29	10953-10954	.	_

63-1	10955-10957	To	_
63-2	10958-10965	further	_
63-3	10966-10973	confirm	_
63-4	10974-10982	regional	_
63-5	10983-10986	GMV	_
63-6	10987-10998	association	_
63-7	10999-11003	with	_
63-8	11004-11010	CRAFFT	_
63-9	11011-11018	outcome	_
63-10	11019-11020	,	_
63-11	11021-11024	the	_
63-12	11025-11037	relationship	_
63-13	11038-11045	between	_
63-14	11046-11050	mean	_
63-15	11051-11054	GMV	_
63-16	11055-11057	in	_
63-17	11058-11069	significant	_
63-18	11070-11078	clusters	_
63-19	11079-11083	with	_
63-20	11084-11089	total	_
63-21	11090-11096	CRAFFT	_
63-22	11097-11102	score	_
63-23	11103-11106	was	_
63-24	11107-11115	assessed	_
63-25	11116-11120	with	_
63-26	11121-11128	Pearson	_
63-27	11129-11141	correlations	_
63-28	11142-11148	across	_
63-29	11149-11152	all	_
63-30	11153-11161	subjects	_
63-31	11162-11163	.	_

64-1	11164-11176	Correlations	_
64-2	11177-11181	were	_
64-3	11182-11190	repeated	_
64-4	11191-11201	stratified	_
64-5	11202-11204	by	_
64-6	11205-11208	sex	_
64-7	11209-11211	to	_
64-8	11212-11219	explore	_
64-9	11220-11231	sex-related	_
64-10	11232-11240	patterns	_
64-11	11241-11243	in	_
64-12	11244-11254	volumetric	_
64-13	11255-11263	features	_
64-14	11264-11274	associated	_
64-15	11275-11279	with	_
64-16	11280-11283	the	_
64-17	11284-11295	development	_
64-18	11296-11298	of	_
64-19	11299-11308	substance	_
64-20	11309-11312	use	_
64-21	11313-11321	problems	_
64-22	11322-11323	.	_

65-1	11324-11335	Correlation	_
65-2	11336-11344	analyses	_
65-3	11345-11349	were	_
65-4	11350-11354	also	_
65-5	11355-11364	performed	_
65-6	11365-11371	across	_
65-7	11372-11375	all	_
65-8	11376-11384	subjects	_
65-9	11385-11386	,	_
65-10	11387-11390	and	_
65-11	11391-11401	stratified	_
65-12	11402-11404	by	_
65-13	11405-11408	sex	_
65-14	11409-11410	,	_
65-15	11411-11413	to	_
65-16	11414-11420	assess	_
65-17	11421-11433	relationship	_
65-18	11434-11441	between	_
65-19	11442-11445	GMV	_
65-20	11446-11449	and	_
65-21	11450-11458	baseline	_
65-22	11459-11463	CDRS	_
65-23	11464-11466	or	_
65-24	11467-11470	BIS	_
65-25	11471-11472	(	_
65-26	11473-11478	total	_
65-27	11479-11482	and	_
65-28	11483-11491	subscale	_
65-29	11492-11493	)	_
65-30	11494-11500	scores	_
65-31	11501-11502	.	_

66-1	11503-11508	Based	_
66-2	11509-11511	on	_
66-3	11512-11515	our	_
66-4	11516-11517	a	_
66-5	11518-11524	priori	_
66-6	11525-11535	hypotheses	_
66-7	11536-11537	,	_
66-8	11538-11541	GMV	_
66-9	11542-11546	from	_
66-10	11547-11555	clusters	_
66-11	11556-11562	within	_
66-12	11563-11570	rostral	_
66-13	11571-11574	PFC	_
66-14	11575-11576	(	_
66-15	11577-11581	rPFC	_
66-16	11582-11583	)	_
66-17	11584-11587	and	_
66-18	11588-11600	dorsolateral	_
66-19	11601-11604	PFC	_
66-20	11605-11606	(	_
66-21	11607-11612	dlPFC	_
66-22	11613-11614	)	_
66-23	11615-11622	showing	_
66-24	11623-11624	a	_
66-25	11625-11636	significant	_
66-26	11637-11647	difference	_
66-27	11648-11655	between	_
66-28	11656-11662	CRAFFT	_
66-29	11663-11669	groups	_
66-30	11670-11674	were	_
66-31	11675-11683	assessed	_
66-32	11684-11687	for	_
66-33	11688-11700	relationship	_
66-34	11701-11705	with	_
66-35	11706-11709	BIS	_
66-36	11710-11711	(	_
66-37	11712-11717	total	_
66-38	11718-11721	and	_
66-39	11722-11731	subscales	_
66-40	11732-11733	)	_
66-41	11734-11740	scores	_
66-42	11741-11742	;	_
66-43	11743-11746	GMV	_
66-44	11747-11751	from	_
66-45	11752-11760	clusters	_
66-46	11761-11767	within	_
66-47	11768-11781	orbitofrontal	_
66-48	11782-11788	cortex	_
66-49	11789-11790	(	_
66-50	11791-11794	OFC	_
66-51	11795-11796	)	_
66-52	11797-11800	and	_
66-53	11801-11808	insular	_
66-54	11809-11812	and	_
66-55	11813-11825	temporopolar	_
66-56	11826-11834	cortices	_
66-57	11835-11839	were	_
66-58	11840-11848	assessed	_
66-59	11849-11852	for	_
66-60	11853-11865	relationship	_
66-61	11866-11870	with	_
66-62	11871-11879	baseline	_
66-63	11880-11884	CDRS	_
66-64	11885-11891	scores	_
66-65	11892-11893	.	_

67-1	11894-11898	Post	_
67-2	11899-11902	hoc	_
67-3	11903-11911	analyses	_
67-4	11912-11917	above	_
67-5	11918-11922	were	_
67-6	11923-11931	repeated	_
67-7	11932-11937	after	_
67-8	11938-11946	removing	_
67-9	11947-11948	3	_
67-10	11949-11957	subjects	_
67-11	11958-11962	with	_
67-12	11963-11964	a	_
67-13	11965-11972	history	_
67-14	11973-11975	of	_
67-15	11976-11983	tobacco	_
67-16	11984-11987	use	_
67-17	11988-11990	at	_
67-18	11991-11999	baseline	_
67-19	12000-12001	.	_

68-1	12002-12003	A	_
68-2	12004-12010	t-test	_
68-3	12011-12014	was	_
68-4	12015-12019	used	_
68-5	12020-12022	to	_
68-6	12023-12030	explore	_
68-7	12031-12042	differences	_
68-8	12043-12045	in	_
68-9	12046-12055	extracted	_
68-10	12056-12059	GMV	_
68-11	12060-12061	,	_
68-12	12062-12066	from	_
68-13	12067-12078	significant	_
68-14	12079-12086	regions	_
68-15	12087-12097	identified	_
68-16	12098-12100	in	_
68-17	12101-12104	the	_
68-18	12105-12111	CRAFFT	_
68-19	12112-12117	group	_
68-20	12118-12126	analysis	_
68-21	12127-12132	above	_
68-22	12133-12134	,	_
68-23	12135-12142	between	_
68-24	12143-12154	individuals	_
68-25	12155-12158	who	_
68-26	12159-12164	never	_
68-27	12165-12171	smoked	_
68-28	12172-12179	tobacco	_
68-29	12180-12182	at	_
68-30	12183-12189	either	_
68-31	12190-12200	assessment	_
68-32	12201-12202	(	_
68-33	12203-12207	N=16	_
68-34	12208-12209	)	_
68-35	12210-12213	and	_
68-36	12214-12219	those	_
68-37	12220-12223	who	_
68-38	12224-12236	transitioned	_
68-39	12237-12239	to	_
68-40	12240-12247	smoking	_
68-41	12248-12255	tobacco	_
68-42	12256-12263	between	_
68-43	12264-12272	baseline	_
68-44	12273-12276	and	_
68-45	12277-12286	follow-up	_
68-46	12287-12297	assessment	_
68-47	12298-12299	(	_
68-48	12300-12304	N=11	_
68-49	12305-12306	)	_
68-50	12307-12308	.	_

69-1	12309-12317	Regional	_
69-2	12318-12321	GMV	_
69-3	12322-12332	identified	_
69-4	12333-12335	as	_
69-5	12336-12341	being	_
69-6	12342-12352	associated	_
69-7	12353-12357	with	_
69-8	12358-12371	transitioning	_
69-9	12372-12374	to	_
69-10	12375-12382	smoking	_
69-11	12383-12390	tobacco	_
69-12	12391-12395	were	_
69-13	12396-12404	explored	_
69-14	12405-12411	across	_
69-15	12412-12415	all	_
69-16	12416-12424	subjects	_
69-17	12425-12428	who	_
69-18	12429-12441	transitioned	_
69-19	12442-12445	and	_
69-20	12446-12450	were	_
69-21	12451-12460	currently	_
69-22	12461-12468	smoking	_
69-23	12469-12476	tobacco	_
69-24	12477-12479	at	_
69-25	12480-12489	follow-up	_
69-26	12490-12495	using	_
69-27	12496-12503	Pearson	_
69-28	12504-12516	correlations	_
69-29	12517-12519	to	_
69-30	12520-12529	determine	_
69-31	12530-12543	relationships	_
69-32	12544-12548	with	_
69-33	12549-12554	total	_
69-34	12555-12559	FTND	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
69-35	12560-12566	scores	_
69-36	12567-12568	.	_

70-1	12569-12571	We	_
70-2	12572-12581	performed	_
70-3	12582-12589	t-tests	_
70-4	12590-12592	to	_
70-5	12593-12600	explore	_
70-6	12601-12613	associations	_
70-7	12614-12621	between	_
70-8	12622-12626	mean	_
70-9	12627-12630	GMV	_
70-10	12631-12633	in	_
70-11	12634-12645	significant	_
70-12	12646-12654	clusters	_
70-13	12655-12659	with	_
70-14	12660-12668	clinical	_
70-15	12669-12672	and	_
70-16	12673-12683	medication	_
70-17	12684-12692	subclass	_
70-18	12693-12700	factors	_
70-19	12701-12708	present	_
70-20	12709-12712	and	_
70-21	12713-12719	absent	_
70-22	12720-12722	at	_
70-23	12723-12731	baseline	_
70-24	12732-12734	in	_
70-25	12735-12736	N	_
70-26	12737-12738	>	_
70-27	12739-12740	5	_
70-28	12741-12749	subjects	_
70-29	12750-12751	,	_
70-30	12752-12761	including	_
70-31	12762-12766	mood	_
70-32	12767-12772	state	_
70-33	12773-12774	(	_
70-34	12775-12783	euthymic	_
70-35	12784-12790	versus	_
70-36	12791-12799	elevated	_
70-37	12800-12801	)	_
70-38	12802-12803	,	_
70-39	12804-12811	history	_
70-40	12812-12813	(	_
70-41	12814-12820	yes/no	_
70-42	12821-12822	)	_
70-43	12823-12825	of	_
70-44	12826-12842	hospitalizations	_
70-45	12843-12844	,	_
70-46	12845-12850	rapid	_
70-47	12851-12858	cycling	_
70-48	12859-12860	,	_
70-49	12861-12869	lifetime	_
70-50	12870-12879	psychosis	_
70-51	12880-12881	,	_
70-52	12882-12885	and	_
70-53	12886-12888	if	_
70-54	12889-12895	taking	_
70-55	12896-12897	(	_
70-56	12898-12904	off/on	_
70-57	12905-12906	)	_
70-58	12907-12909	an	_
70-59	12910-12923	antipsychotic	_
70-60	12924-12925	,	_
70-61	12926-12940	anticonvulsant	_
70-62	12941-12942	,	_
70-63	12943-12952	stimulant	_
70-64	12953-12954	,	_
70-65	12955-12962	lithium	_
70-66	12963-12964	,	_
70-67	12965-12979	antidepressant	_
70-68	12980-12981	,	_
70-69	12982-12984	or	_
70-70	12985-12999	benzodiazepine	_
70-71	13000-13001	.	_

71-1	13002-13010	Analyses	_
71-2	13011-13015	were	_
71-3	13016-13024	repeated	_
71-4	13025-13035	stratified	_
71-5	13036-13038	by	_
71-6	13039-13042	sex	_
71-7	13043-13046	for	_
71-8	13047-13055	clinical	_
71-9	13056-13063	factors	_
71-10	13064-13071	present	_
71-11	13072-13074	or	_
71-12	13075-13081	absent	_
71-13	13082-13084	at	_
71-14	13085-13093	baseline	_
71-15	13094-13096	in	_
71-16	13097-13098	N	_
71-17	13099-13100	>	_
71-18	13101-13102	5	_
71-19	13103-13109	female	_
71-20	13110-13112	or	_
71-21	13113-13117	male	_
71-22	13118-13126	subjects	_
71-23	13127-13128	,	_
71-24	13129-13138	including	_
71-25	13139-13146	history	_
71-26	13147-13148	(	_
71-27	13149-13155	yes/no	_
71-28	13156-13157	)	_
71-29	13158-13160	at	_
71-30	13161-13169	baseline	_
71-31	13170-13172	of	_
71-32	13173-13178	rapid	_
71-33	13179-13186	cycling	_
71-34	13187-13188	,	_
71-35	13189-13197	lifetime	_
71-36	13198-13207	psychosis	_
71-37	13208-13209	,	_
71-38	13210-13213	and	_
71-39	13214-13216	if	_
71-40	13217-13223	taking	_
71-41	13224-13225	(	_
71-42	13226-13232	off/on	_
71-43	13233-13234	)	_
71-44	13235-13237	an	_
71-45	13238-13251	antipsychotic	_
71-46	13252-13254	at	_
71-47	13255-13263	baseline	_
71-48	13264-13265	.	_

72-1	13266-13268	In	_
72-2	13269-13276	females	_
72-3	13277-13278	,	_
72-4	13279-13281	we	_
72-5	13282-13290	assessed	_
72-6	13291-13298	effects	_
72-7	13299-13301	of	_
72-8	13302-13308	taking	_
72-9	13309-13311	an	_
72-10	13312-13326	anticonvulsant	_
72-11	13327-13330	and	_
72-12	13331-13342	differences	_
72-13	13343-13350	between	_
72-14	13351-13359	subjects	_
72-15	13360-13373	transitioning	_
72-16	13374-13376	to	_
72-17	13377-13384	smoking	_
72-18	13385-13392	tobacco	_
72-19	13393-13400	between	_
72-20	13401-13409	baseline	_
72-21	13410-13413	and	_
72-22	13414-13423	follow-up	_
72-23	13424-13435	assessments	_
72-24	13436-13437	(	_
72-25	13438-13441	N=7	_
72-26	13442-13449	females	_
72-27	13450-13451	)	_
72-28	13452-13453	,	_
72-29	13454-13462	compared	_
72-30	13463-13465	to	_
72-31	13466-13471	those	_
72-32	13472-13481	reporting	_
72-33	13482-13484	no	_
72-34	13485-13492	history	_
72-35	13493-13495	of	_
72-36	13496-13503	smoking	_
72-37	13504-13506	at	_
72-38	13507-13513	either	_
72-39	13514-13524	assessment	_
72-40	13525-13526	(	_
72-41	13527-13530	N=6	_
72-42	13531-13538	females	_
72-43	13539-13540	)	_
72-44	13541-13542	.	_

73-1	13543-13545	In	_
73-2	13546-13551	males	_
73-3	13552-13553	,	_
73-4	13554-13556	we	_
73-5	13557-13565	assessed	_
73-6	13566-13573	effects	_
73-7	13574-13576	of	_
73-8	13577-13585	comorbid	_
73-9	13586-13590	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
73-10	13591-13594	and	_
73-11	13595-13601	taking	_
73-12	13602-13603	a	_
73-13	13604-13613	stimulant	_
73-14	13614-13616	or	_
73-15	13617-13624	lithium	_
73-16	13625-13627	at	_
73-17	13628-13636	baseline	_
73-18	13637-13647	assessment	_
73-19	13648-13649	,	_
73-20	13650-13653	but	_
73-21	13654-13657	did	_
73-22	13658-13661	not	_
73-23	13662-13668	assess	_
73-24	13669-13672	for	_
73-25	13673-13680	smoking	_
73-26	13681-13691	conversion	_
73-27	13692-13694	as	_
73-28	13695-13699	only	_
73-29	13700-13701	4	_
73-30	13702-13707	males	_
73-31	13708-13717	converted	_
73-32	13718-13719	.	_

74-1	13720-13725	These	_
74-2	13726-13730	post	_
74-3	13731-13734	hoc	_
74-4	13735-13743	analyses	_
74-5	13744-13748	were	_
74-6	13749-13759	considered	_
74-7	13760-13771	significant	_
74-8	13772-13774	at	_
74-9	13775-13776	p	_
74-10	13777-13778	<	_
74-11	13779-13783	0.05	_
74-12	13784-13785	.	_

75-1	13786-13789	All	_
75-2	13790-13801	significant	_
75-3	13802-13809	results	_
75-4	13810-13813	are	_
75-5	13814-13822	reported	_
75-6	13823-13828	below	_
75-7	13829-13830	.	_

